United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 5 minute read General business news Man Infraconstruction stock watch: Is FY25 performance a signal for long-term investors? Man Infraconstruction tripled FY25 sales and rewarded shareholders with dividends. Is the momentum sustainable into FY26? Read the full investor outlook here. byPallavi MadhirajuMay 28, 2025